Singapore a top draw for Pfizer as it looks to invest for the long run


FILE PHOTO: A view of the skyline in Singapore, January 27, 2023. REUTERS/Caroline Chia/File Photo

SINGAPORE: Singapore is not a low-cost manufacturing base, but good infrastructure, respect for intellectual property, access to talent, and a government with a vision are what makes it the go-to destination for US pharma giant Pfizer.

“There are no short-term investments in the world of pharmaceuticals,” said Mike McDermott, chief global supply officer and executive vice-president of Pfizer.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Singapore , manufacturing , pharma , Pfizer

Next In Business News

Doubts over Viet reform drive
Leadership exodus tests Malaysia’s digital banks
Capitalising on the tourism momentum
South African beauty market gets makeover
Navigating Fed uncertainty
Indonesia MSCI alert sends ripples to Malaysia
Chinese tea chains pour into US
Blazing a trail for fire safety
Turning footfall into higher profits
Bond buys fall flat

Others Also Read